Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 5 Similar Profiles
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Interferon-alpha Medicine & Life Sciences
Philadelphia Chromosome Medicine & Life Sciences
Cytogenetics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Leukemia, Myeloid, Chronic Phase Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 1997 2026

Research Output 1979 2017

Exome
Primary Myelofibrosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transcriptome
Neoplasms
1 Citations

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias

Cortes, J. E., Gambacorti-Passerini, C., Kim, D. W., Kantarjian, H. M., Lipton, J. H., Lahoti, A., Talpaz, M., Matczak, E., Barry, E., Leip, E., Brümmendorf, T. H. & Khoury, H. J. Oct 1 2017 In : Clinical Lymphoma, Myeloma and Leukemia. 17, 10, p. 684-695.e6

Research output: Research - peer-reviewArticle

Philadelphia Chromosome
Leukemia
Kidney
Therapeutics
bosutinib

Induction of p53 suppresses chronic myeloid leukemia

Peterson, L. F., Lo, M. C., Liu, Y., Giannola, D., Mitrikeska, E., Donato, N. J., Johnson, C. N., Wang, S., Mercer, J. & Talpaz, M. Sep 2 2017 In : Leukemia and Lymphoma. 58, 9, p. 2165-2175 11 p.

Research output: Research - peer-reviewArticle

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
MI-219
Philadelphia Chromosome
Genetic Translocation
1 Citations

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Harrison, C. N., Schaap, N., Vannucchi, A. M., Kiladjian, J. J., Tiu, R. V., Zachee, P., Jourdan, E., Winton, E., Silver, R. T., Schouten, H. C., Passamonti, F., Zweegman, S., Talpaz, M., Lager, J., Shun, Z. & Mesa, R. A. Jul 1 2017 In : The Lancet Haematology. 4, 7, p. e317-e324

Research output: Research - peer-reviewArticle

Janus Kinase 2
Primary Myelofibrosis
Multicenter Studies
INCB018424
TG101348
7 Citations

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Verstovsek, S. , Mesa, R. A. , Gotlib, J. , Gupta, V. , DiPersio, J. F. , Catalano, J. V. , Deininger, M. W. N. , Miller, C. B. , Silver, R. T. , Talpaz, M. , Winton, E. F. , Harvey, J. H. , Arcasoy, M. O. , Hexner, E. O. , Lyons, R. M. , Paquette, R. , Raza, A. , Jones, M. , Kornacki, D. , Sun, K. & 1 others Kantarjian, H. Feb 22 2017 In : Journal of Hematology and Oncology. 10, 1, p. 1-14 14 p.

Research output: Research - peer-reviewArticle

Primary Myelofibrosis
Placebos
Therapeutics
INCB018424
Spleen